AFMD vs. IFRX, BRNS, PRPH, GNLX, LPTX, ONCY, CMRX, VACC, VTVT, and ASRT
Should you be buying Affimed stock or one of its competitors? The main competitors of Affimed include InflaRx (IFRX), Barinthus Biotherapeutics (BRNS), ProPhase Labs (PRPH), Genelux (GNLX), Leap Therapeutics (LPTX), Oncolytics Biotech (ONCY), Chimerix (CMRX), Vaccitech (VACC), vTv Therapeutics (VTVT), and Assertio (ASRT). These companies are all part of the "pharmaceutical preparations" industry.
Affimed (NASDAQ:AFMD) and InflaRx (NASDAQ:IFRX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, community ranking, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.
Affimed received 198 more outperform votes than InflaRx when rated by MarketBeat users. Likewise, 69.92% of users gave Affimed an outperform vote while only 64.09% of users gave InflaRx an outperform vote.
30.8% of Affimed shares are held by institutional investors. Comparatively, 42.4% of InflaRx shares are held by institutional investors. 3.8% of Affimed shares are held by company insiders. Comparatively, 16.3% of InflaRx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Affimed presently has a consensus target price of $45.00, suggesting a potential upside of 760.42%. InflaRx has a consensus target price of $13.50, suggesting a potential upside of 1,025.00%. Given InflaRx's stronger consensus rating and higher probable upside, analysts plainly believe InflaRx is more favorable than Affimed.
InflaRx has lower revenue, but higher earnings than Affimed. InflaRx is trading at a lower price-to-earnings ratio than Affimed, indicating that it is currently the more affordable of the two stocks.
InflaRx has a net margin of 0.00% compared to Affimed's net margin of -1,280.27%. InflaRx's return on equity of -40.10% beat Affimed's return on equity.
Affimed has a beta of 2.05, indicating that its stock price is 105% more volatile than the S&P 500. Comparatively, InflaRx has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500.
In the previous week, InflaRx had 3 more articles in the media than Affimed. MarketBeat recorded 4 mentions for InflaRx and 1 mentions for Affimed. Affimed's average media sentiment score of 1.34 beat InflaRx's score of -0.32 indicating that Affimed is being referred to more favorably in the media.
Summary
InflaRx beats Affimed on 12 of the 19 factors compared between the two stocks.
Get Affimed News Delivered to You Automatically
Sign up to receive the latest news and ratings for AFMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AFMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
